Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

This review outlines current treatment strategies for trichotillomania, noting cognitive-behavioral therapy's success, while highlighting the promise and limitations of various pharmacological options.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

The AUTS2 gene is linked to neurological disorders and may affect human brain development and cognition.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This study explains that while trichothiodystrophy and xeroderma pigmentosum share genetic defects, TTD patients primarily exhibit issues in transcription initiation, not the increased skin cancer risk seen in XP.

This case report discusses the diagnostic challenges and management options for three siblings with 46, XY DSD due to type 2 5-α reductase deficiency, highlighting the genetic basis and impact on their quality of life.

This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.

This report describes an 8-year-old male with trichotillomania, confirmed by trichoscopy showing characteristic hair damage and patterns.

In this study, researchers reviewed current treatments for trichotillomania and found that psychotherapy, particularly cognitive-behavioral therapy like habit reversal training, is most effective, with some medications helping to alleviate symptoms, though further study is needed on their use.

In this study, researchers found that TCDD exposure accelerated differentiation and altered gene expression in human epidermal cells, indicating the epidermal barrier as a target of TCDD-activated AHR.

In this case report, Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, but both developed symptoms of Cushing's Syndrome, prompting the need for careful monitoring due to potential adverse effects when using this treatment.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This case report details a 28-year-old male who developed trichotillomania following a traumatic brain injury, highlighting diagnostic challenges in distinguishing overlapping psychiatric and compulsive behaviors, and underscores the importance of a comprehensive, multidisciplinary treatment approach.

This study established a new mouse model for TCE-induced skin sensitization and reported that proinflammatory cytokines TNF-α, IFN-γ, and IL-2 significantly contribute to this sensitization process.

This review discusses recent advancements in behavioral and pharmacological treatments for trichotillomania but does not report new clinical results, emphasizing the need for rigorous future research.

This case report describes improvement in amenorrhea, alopecia, and muscle spasms in a 13-year-old girl with Satoyoshi syndrome following treatment with daily tacrolimus and alternate-day oral prednisolone.

This study found that a single application of TCDD on the skin of hairless mice altered epidermal differentiation, changing keratin expression patterns similarly to a known tumor promoter.

The researchers identified a pathogenic variant in the SRD5A2 gene among siblings with 46,XY disorder of sexual development, highlighting the importance of comprehensive genetic testing in diagnosis and management.

This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This publication reviews the World Professional Association for Transgender Health's Standards of Care for supporting transgender and gender nonconforming people, with adjustments needed for diverse global contexts and no new clinical results.

This study suggests that SRD5A2 polymorphisms may increase the risk of acne in individuals with normal serum testosterone levels, particularly in the Chinese population.

In this case-control study, researchers did not find genome-wide significant genetic variants for trichotillomania, but cases had higher polygenic risk for psychiatric disorders and certain neuropsychiatric-associated copy number variants.

This case report describes a 3-year-old boy with trichothiodystrophy, highlighting specific MRI findings of diffuse dysmyelination and osteosclerosis that may be unique to the disorder.

Toxic Shock Syndrome progresses quickly, often involves multiple organs, and is linked to Staphylococcus aureus toxins, with treatment options available but diagnostic challenges remaining.

This review covers cross-sex hormone therapy for gender dysphoria, noting improvements in psychological symptoms and quality of life but lacking definitive long-term safety data.

This case report describes two instances of habit tic nail deformities associated with alopecia areata.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.